Join Growin Stock Community!

Monopar therapeutics inc.MNPR.US Overview

US StockHealthcare
(No presentation for MNPR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MNPR AI Insights

MNPR Overall Performance

MNPR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MNPR Recent Performance

-1.93%

Monopar therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

MNPR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MNPR Key Information

MNPR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MNPR Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Price of MNPR

MNPR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MNPR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.59
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.59
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MNPR's latest earnings report released?

    The most recent financial report for Monopar therapeutics inc. (MNPR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MNPR's short-term business performance and financial health. For the latest updates on MNPR's earnings releases, visit this page regularly.

  • How much cash does MNPR have?

    At the end of the period, Monopar therapeutics inc. (MNPR) held Total Cash and Cash Equivalents of 127.68M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MNPR's EPS continuing to grow?

    According to the past four quarterly reports, Monopar therapeutics inc. (MNPR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MNPR?

    Monopar therapeutics inc. (MNPR)'s Free Cash Flow (FCF) for the period is -2.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 94.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MNPR?

    The latest valuation data shows Monopar therapeutics inc. (MNPR) has a Price-To-Earnings (PE) ratio of -29.91 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.